All In Biotech

Drug Trial Radar · NCT07224373

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Dec 12, 2028

Study completion Dec 12, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with relapsing and progessive Multiple Sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • AZD0120 - Regimen 1Biological

    Regimen 1, infusion of AZD0120

  • AZD0120 - Regimen 2Biological

    Regimen 2, infusion of AZD0120

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Time frame: Day 1 to day 29
  2. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Time frame: Day 1 to day 29, and over 104 weeks
  3. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Time frame: Day 1 to day 29, and over 104 weeks
  4. Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)Time frame: Day 1 to day 29, and over 104 weeks

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona · Withdrawn

  • Research Site

    Aurora, Colorado · Not yet recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Milwaukee, Wisconsin · Recruiting

  • Research Site

    Liverpool, Australia · Not yet recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Not yet recruiting

  • Research Site

    Waratah, Australia · Not yet recruiting

  • Research Site

    Montreal, Quebec, Canada · Not yet recruiting

  • Research Site

    Leipzig, Germany · Withdrawn

  • Research Site

    Magdeburg, Germany · Withdrawn

  • Research Site

    Würzburg, Germany · Withdrawn

  • Research Site

    Cambridge, United Kingdom · Withdrawn

  • Research Site

    London, United Kingdom · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.